Details business of pathways, including, but not limited to financing and payment incentives, HEOR, predictable cost of care (PCOC), and cost modeling.
Oncology pathways have reduced some variation in care, but growing evidence suggests that proprietary pathway programs may now be contributing to administrative burden and fragmentation, prompting a reexamination of how payers and providers...
Oncology pathways have reduced some variation in care, but growing evidence suggests that proprietary pathway programs may now be contributing to administrative burden and fragmentation, prompting a reexamination of how payers and providers...
This column explores how AI is redefining clinical pathways, offering new opportunities to improve patient care, control costs, and address the structural challenges facing today's health care system.
This column explores how AI is redefining clinical pathways, offering new opportunities to improve patient care, control costs, and address the structural challenges facing today's health care system.
Lucio Gordan, MD; Kiana Mehring, MBA, PPMC; David T. Wenk, MD; Josh Eaves; Ryan Ciarrocchi
This study reveals how increasing payer control over oncology treatments is driving delays and administrative burden, undermining evidence-based, physician-led care and timely patient access.
This study reveals how increasing payer control over oncology treatments is driving delays and administrative burden, undermining evidence-based, physician-led care and timely patient access.
As double-digit cost increases collide with economic uncertainty, employers are turning to data-driven clinical pathways to better control spending, improve outcomes, and shape more targeted health benefits for 2027.
As double-digit cost increases collide with economic uncertainty, employers are turning to data-driven clinical pathways to better control spending, improve outcomes, and shape more targeted health benefits for 2027.
In this episode of The Pathways Guys Podcast, our hosts cover Medicare Part D formularies in oncology, explaining how pharmacy benefit managers design drug coverage and how this impacts oncology market access, reimbursement, and patient care.
In this episode of The Pathways Guys Podcast, our hosts cover Medicare Part D formularies in oncology, explaining how pharmacy benefit managers design drug coverage and how this impacts oncology market access, reimbursement, and patient care.
This Online Exclusive features the debut episode of The Pathways Guys podcast, a series exploring the real-world impact of clinical pathways on oncology policy, payment, and practice.
This Online Exclusive features the debut episode of The Pathways Guys podcast, a series exploring the real-world impact of clinical pathways on oncology policy, payment, and practice.
This column discusses how shifting federal policy, employer health plan economics, and rising drug costs in 2026 will reshape business decisions that directly influence oncology access, affordability, and clinical pathway sustainability.
This column discusses how shifting federal policy, employer health plan economics, and rising drug costs in 2026 will reshape business decisions that directly influence oncology access, affordability, and clinical pathway sustainability.
Gordon Kuntz provides a recap of the 9th annual Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), highlighting important themes and notable sessions.
Gordon Kuntz provides a recap of the 9th annual Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), highlighting important themes and notable sessions.
In this column, F. Randy Vogenberg, PhD, FASHP, reviews health care stakeholders’ final priorities for 2025 and the transition to a more complex business-driven shift in risk mitigation for 2026 health care coverage.
In this column, F. Randy Vogenberg, PhD, FASHP, reviews health care stakeholders’ final priorities for 2025 and the transition to a more complex business-driven shift in risk mitigation for 2026 health care coverage.
As unprecedented medical and technological advances outpace existing care and reimbursement models, employers and manufacturers must collaborate through data-driven, trust-based frameworks to ensure equitable access to care.
As unprecedented medical and technological advances outpace existing care and reimbursement models, employers and manufacturers must collaborate through data-driven, trust-based frameworks to ensure equitable access to care.